What is the risk of infection associated with BCMA directed therapies?

What is the risk of infection associated with BCMA directed therapies?
Efficacy of Navitoclax and Ruxolitinib | Naveen Pemmaraju, MD | EHA 2024
Discussing the Unmet Clinical Needs in 2 Special CLL Patient Groups | Silvia Deaglio, MD | EHA 2024